And there are some good examples of this, this quarter, Sanofi or Amgen ... an expansion of MEDIDATA with some key players such as Regeneron and new customers like Merck KGaA, and I will come ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...